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Introduction
Skeletal muscle is an ideal seeding site for the treatment of primary myopathies or diseases requiring production of circulating proteins because it is highly vascular and an excellent secretory organ with many accessible sites. [1] [2] [3] [4] [5] [6] [7] [8] Moreover, the post-mitotic nature and longevity of muscle fibers permits stable expression of transferred genes, even if they are not integrated into chromosomal DNA. 9, 10 High level gene expression in a relatively small number of muscle fibers may be adequate to treat inherited or acquired metabolic disorders, or to induce an immune response sufficient for vaccination. 11 Gene transfer to skeletal muscles has been hampered in part due to the inability of current generation vectors to infect a significant number of cells. [12] [13] [14] [15] [16] [17] [18] [19] Although adeno-associated virus (AAV) efficiently infects muscle and elicits sustained gene expression, its capacity for delivering and regulating large genes is limited. As for the large DNA viruses such as HSV and adenovirus, muscle fibers exhibit a maturation-dependent loss of susceptibility to infection. 15, [20] [21] [22] [23] [24] [25] [26] [27] [28] Previous studies of HSV infection in the rodent show that the loss of infectivity may be due, at least in part, to the development of the basal lamina throughout the course of maturation, which may block the initial events in HSV infection. 23 To initiate infection, HSV attaches to cell surface glycosaminoglycans such as heparan sulfate and dermatan sulfate, [29] [30] [31] [32] [33] [34] [35] which stabilize the virus such that is can interact with secondary protein receptors required for entry into host cells. [36] [37] [38] Thus, one possibility to account for the loss of susceptibility to HSV infection is that maturation leads to a decrease in the expression of cell surface molecules required for efficient infection.
In this study, we demonstrate that glycosaminoglycan synthesis is down-regulated during murine skeletal muscle maturation. This could account for the loss of HSV infectivity because heparan sulfate acts as a co-receptor for attachment of HSV to cells. [38] [39] [40] To test whether secondary HSV receptors were present, myofibers were treated with a variety of enzymes, including collagenase type IV and chondroitin ABC lyase. Both of these treatments enhanced HSV infection, which suggests that virus receptors were present but not readily accessible to the virus in the intact myofiber. Surprisingly, we also found that infectivity of HSV-1, but not HSV type 2 (HSV-2), could be restored by exposing myofibers to low concentrations of the glycosaminoglycan analog dextran sulfate. Dextran sulfate has been shown previously to promote HSV-1 but not HSV-2 infection in the absence of heparan sulfate. This supports the hypothesis that a lack of accessible heparan sulfate is responsible for the resistance of mature myofibers to HSV-1 infection. Taken together, these results show that the basal lamina is not an absolute block to infection, and that dextran sulfate can be used as a surrogate co-receptor for the nondestructive targeting of HSV-1 to mature skeletal muscle. These findings greatly expand the usefulness of HSV as a gene therapy vector for the treatment of inherited and acquired diseases.
Results
Mature myofibers are refractory to infection It has been shown previously that HSV vectors infect newborn muscle fibers in vitro, but not those isolated from older animals. [20] [21] [22] [23] To investigate the underlying basis for the maturation-dependent loss of infection, single muscle fibers were established in culture, and exposed to G207, which is an attenuated replicationdefective HSV-1 vector that expresses ␤-galactosidase following infection. 41, 42 In these assays, newborn myofibers were completely susceptible to infection, whereas only 6% of mature myofibers were infected at this concentration of virus (Table 1 and Figure 1a and b). Thus, these results were consistent with previous studies showing a maturation-dependent loss of susceptibility to HSV infection. 21, 23 Approaches to rescue adult skeletal muscle infectivity Previous studies have suggested that basal lamina formation during maturation may act as a physical barrier to HSV infection, thereby preventing interaction of the virus with the receptors required for infectivity. To test this, isolated myofibers were exposed to G207 following treatment with collagenase type IV, which liberates peptides from collagen thereby degrading the basal lamina ( Figure  1 ). Indirect immunofluorescence of a nuclear HSV protein, ICP4, revealed that partial destruction of the basal lamina in this manner stimulated HSV infection ( Figure  1d ). The effect was concentration dependent such that an increase in collagenase type IV correlated with an increase in HSV infection. Toxicity occurred at 0.66 mg/ml as indicated by myofiber hypercontraction during the 30 min preincubation period (Table 1) . In a second approach, chondroitin ABC lyase, which degrades a broad range of chondroitin sulfate moieties, was tested for its ability to enhance susceptibility to HSV infection (Figure 1g and h). This treatment strongly enhanced infection, whereas treatment with heparitinase did not (Table 1) . Thus, partial destruction of the basal lamina with specific enzymes allowed for the attachment and entry of HSV into the mature muscle fiber, which suggests that virus secondary receptors were present but not accessible in the context of the mature myofiber.
Analysis of cell surface glycosaminoglycans HSV infects cells by attaching to cell surface heparan sulfate-like moieties followed by interaction with secondary protein receptors. 29, 32, 37, 38 Although not strictly required, cell surface heparan sulfate increases the efficiency of HSV infection by two orders-of-magnitude in most cells tested. 43 To investigate whether glycosaminoglycan expression was altered in adult versus newborn muscle fibers, radiolabeled glycosaminoglycans were isolated from muscle fiber cultures and analyzed by anion exchange HPLC (Figure 2 ). Newborn muscle fibers expressed significant amounts of heparan sulfate and chondroitin sulfate glycosaminoglycans. By contrast, glycosaminoglycan synthesis was significantly reduced in adult myofibers during steady-state labeling, and the residual heparan sulfate synthesized was relatively under-sulfated compared with newborn myofibers (Figure 2 ).
Dextran sulfate restores HSV infection in mature myofibers
The data so far indicated that one or more components of the basal lamina present in mature myofibers inhibited HSV infection. Moreover, heparan sulfate biosynthesis was reduced compared with immature myofibers, which could account for all or part of the loss of susceptibility to HSV infection. It has been shown previously that cells devoid of heparan sulfate biosynthesis can be infected with HSV-1, but not HSV-2, if a low concentration of dextran sulfate is added to the cells either before or during infection. 44 By contrast, dextran sulfate is a potent inhibitor of HSV infection if the target cells express significant amounts of heparan sulfate. When dextran sulfate was added to mature myofibers in culture, HSV-1 infection was significantly enhanced (Figure 1e and f, and Table  1 ). Moreover, this effect was specific for HSV-1, which is consistent with the hypothesis that the lack of mature myofiber infection was due, at least in part, to a lack of accessible heparan sulfate moieties on the cell surface (Table 2) .
To test whether there was an additional block in the post-attachment fusion of HSV with the plasma membrane, isolated mature myofibers were exposed to the fusogenic agent polyethylene-glycol (PEG) before challenge with G207. PEG-induced fusion did not alter adult myofiber infectivity, suggesting that the block to HSV infection occurred at the level of viral attachment (Table 1) .
Infection of skeletal muscle
To establish that immature myofibers were susceptible to G207 infection in vivo, 10 6 plaque forming units (p.f.u.) were injected directly into the tibialis anterior (TA) muscle of an 8-day-old balb/c mouse. Injected muscles were removed 3 days after injection, sectioned, and analyzed histochemically for the expression of ␤-galactosidase ( Figure 3 ). High levels of transgene expression were detected in the injected area. HSV-infected myofibers were also found away from the site of injection, which suggests that there was considerable spread of the vector.
To test whether the three treatments that enhanced infection in vitro worked in the adult animal, mice were injected with 10 6 p.f.u. of G207 in the TA muscle along with either chondroitin ABC lyase, collagenase type IV, or dextran sulfate. In all instances, the in vivo results were consistent with the observations made in vitro ( Figure 4 , Table 3 ). Interestingly, dextran sulfate could be administered an hour before virus with no loss of function, an observation also made in vitro. 44 In addition, infection was not limited to regenerating myofibers, which were identified by their centrally located nuclei. Taken together, these results show that the barrier to HSV infection in adult skeletal muscle was due, at least in part, to the relative paucity of HSV receptors required for efficient infection.
Discussion
The use of muscle as an ectopic site for the production of recombinant proteins has applications for many diseases. 4, [6] [7] [8] [9] Expression of therapeutic proteins in even a small number of myofibers may be adequate to treat inherited or acquired metabolic disorders, or to induce an immune response in the context of a vaccine. 45, 46 Effective methods for muscle gene transfer require vector systems that transduce cells with high efficiency and allow for persistent transgene expression. However, viral vectors such as HSV and adenovirus possess limited ability to infect mature skeletal muscle.
We have shown that efficient infection of mature, highly differentiated myofibers by HSV vectors depends, at least in part, on the display of appropriate receptors on the cell surface. HSV, like several other pathogens, attaches to the host cell via heparan sulfate moieties displayed on the cell surface. 29, 30 Interactions with secondary protein receptors lead to fusion with the plasma mem- brane and a productive infection. 37 Our results indicate that maturation-dependent changes in heparan sulfate on the myofiber cell surface reduce the ability of HSV to infect these cells. This conclusion is supported by the demonstration that soluble dextran sulfate stimulates HSV infection. Heparan sulfate proteoglycans interact with a wide variety of ligands, including growth factors, cytokines, and other regulatory proteins, and it is not surprising to find an alteration in the expression of these moieties during differentiation and maturation. Previous studies have shown that skeletal muscle differentiation is accompanied by a down-regulation of perlecan, a proteoglycan involved in the activation of tyrosine kinase receptors by basic fibroblast growth factor (bFGF). 47 Perlecan expression appears to remain stable during maturation, however. 23 More recently, it has been shown that several GlcNAc N-deacetylase/N-sulfotransferase (NDST) genes are expressed poorly or not at all in mature skeletal muscle. 48 These genes encode isozymes that catalyze crucial reactions in the heparan sulfate/heparin biosynthesis pathways that lead ultimately to the formation of oligosaccharide sequences with specific ligand binding properties. The loss or modification of these and potentially other heparan sulfate biosynthetic activities could account, at least in part, for the loss of susceptibility to HSV infection that we observed.
AAV has also been shown to use heparan sulfate as a co-receptor to gain entry to cells, 49, 50 and is capable of infecting mature myofibers quite efficiently. [51] [52] [53] [54] There are several possibilities to account for this difference. The relatively small size of AAV compared with HSV (20 nm versus 200 nm) may allow it to penetrate the basal lamina better to engage its cognate receptors. Alternatively, AAV may not have as stringent a requirement for heparan sulfate moieties as does HSV to infect cells efficiently. Additional studies of the precise requirements for AAV versus HSV will be required to understand the differences in muscle susceptibility for these two viruses.
More importantly, however, our results show that the basal lamina is not an absolute block to HSV infection. Dextran sulfate, a highly sulfated glycosaminoglycan analog, was capable of stimulating HSV-1 infection, sug- which is interesting because dextran sulfate is normally a potent inhibitor of enveloped virus infection. 34, 43, 44 It appears that in the absence of heparan sulfate, dextran sulfate is able to bind to the virus and to the host cell, thereby tethering the virus to the cell surface. This allows the virus to establish multivalent contacts with additional protein receptors required for a productive infection. HSV-2 has been shown to lack this ability, 44 and our results in myofibers are consistent in this regard. Thus, mature myofibers behave, in vitro and in vivo, as if they are relatively deficient in cell surface heparan sulfate, a result confirmed by HPLC analysis. Moreover, enzymatic digestion of chondroitin sulfate moieties or collagen type IV may stimulate infection (Table 1 and Figure 1 ) by exposing an underlying receptor, or by removing an inhibitory molecule. Dextran sulfate obviates the need to remove these moieties, which shows that HSV receptors are accessible without destroying the mature myofiber.
Previous studies have shown that gene delivery to muscle using viral vectors can elicit marked inflammatory responses that lead to a significant decline in the number of transduced myofibers. This lack of persistence of transgene expression is likely due to the elimination of transduced myofibers by the host immune response: cytotoxic CD4
+ and CD8 + T cells and activated macrophages. 20, 22, 55 Adequate immunosuppression may be necessary to overcome this limitation of viral gene transfer. In fact, administration of immunosuppressive agents such as CTLA4Ig and FK506 has been shown to sustain transgene expression after adenovirus injection in skeletal muscle. 56, 57 However, preliminary studies with HSV amplicons have yielded successful results with our treatments. The use of non-replicating, relatively non-toxic HSV amplicons with our proposed treatments could further alleviate the immunogenicity of foreign protein expression in skeletal muscle.
We have also shown in vitro, that infected myoblasts remaining in the culture are not responsible for the efficient myofiber transduction that we observe. Treatment of the myofiber culture with cytosine arabinoside kills myoblasts, but does not abrogate infection with dextran sulfate (data not shown). Moreover, HSV-2 infects myoblasts and immature myofibers in culture quite efficiently, and yet does not infect mature myofibers. In vivo, the use of collagenase type IV does in fact result in gross muscle damage, as indicated by hematoma formation in the injection area. Although this may indicate that myoblast-mediated infection of myofibers may be possible, one would expect increased myofiber transduction with increased collagenase type IV concentration. This does not occur. In fact, none of the proposed treatments yield higher transduction efficiency with higher concentrations of treatment. Moreover, dextran sulfate and chondroitin ABC lyase appear to be relatively non-toxic following muscle administration. Dextran sulfate is currently being used for treatment of arteriosclerosis, as well as being considered a possible treatment for AIDS.
The ability of dextran sulfate to stimulate HSV-1 infection of mature muscle tissue is important because it is non-destructive, non-toxic, and it limits the spread of the vector from disseminating to other sites in the muscle. Therefore, this represents an approach for targeted expression of HSV vectors to muscle fibers by direct injection. HSV is attractive as a gene delivery vector because its large size allows for the delivery of several large genes at once, and it can be made relatively nontoxic. 22, 58 Moreover, HSV can be grown to high titers, can infect nondividing cells efficiently, 59 and can be controlled through the action of antiviral drugs, such as acyclovir, that inactivate virus replication. [60] [61] [62] This study shows that HSV can efficiently transfer genes to mature muscle cells in vitro and in vivo, and lays the groundwork for the expanded use of HSV as a gene delivery vector. Moreover, elucidation of the biological basis for the critical age-dependent mechanism that restricts infectivity of mature skeletal muscle tissue provides basic insight into muscle cell biology and development, with potentially important therapeutic implications.
Materials and methods

Materials
Dextran sulfate with a molecular weight of 500 000 was purchased from Pharmacia (Baie d'Urfé, Quebec, Canada; catalog No. 17-0340-01). Chondroitin ABC lyase was purchased from Seikagaku (Tokyo, Japan; catalog No. 100330). Heparitinase was purchased from Seikagaku (catalog No. 100703). Collagenase type IV and protease were purchased from Sigma (St Louis, MO, USA; catalog No. C 1889). All tissue culture reagents and dishes were obtained from Canadian Life Technologies (Burlington, Ontario, Canada).
Viral stocks
Recombinant HSV-1, G207 (Neuro Vir), and HSV-2, L1BR1, 63, 64 were prepared on Vero cells. G207 contains the ␤-galactosidase gene inserted in-frame in the ribonucleotide reductase gene. As such, this recombinant virus is unable to replicate in non-dividing cells. L1BR1 contains the ␤-galactosidase gene inserted into the US3 protein kinase gene. Virus was concentrated by centrifugation through a 30% sucrose pad, suspended in phosphate buffered saline (PBS), and filtered through a 0.45 m filter (Sartorius).
The final titer of infectious virus used for all experiments was 1 × 10 8 p.f.u./ml.
Primary muscle fiber cultures
Balb/c mice were bred in institutional animal care facilities at the University of British Columbia. Two different age groups were designated to be 'newborn' and 'adult'. The 'newborn' mice were 7 to 10 days old. The 'adult' mice were 6 to 12 weeks old. Single isolated myofibers were prepared from dissected extensor digitorum longus (EDL) muscle. The myofibers were dissociated by enzymatic disaggregation in 0.2% type 1 collagenase, followed by mild trituration. Isolated myofibers were then plated into several 24-well dishes coated with 1 mg/ml of Matrigel (Collaborative Biomedical Products, Bedford, MA, USA). Culture medium consisting of 10% horse serum and 10% FBS in DMEM was added to the wells. These plates were then incubated for 18 h at 37°C, at which point viable myofibers were infected with G207.
Infection of myofibers
Myofibers were infected by adding G207 (10 6 p.f.u.) in culture medium (10% FBS in DMEM) directly to the wells. Incubation length was overnight (approximately 18 h), although a 1 h infection in DMEM only was sufficient to give reproducible infection. Following incubation, myofibers were fixed for 15 min in 1.25% glutaraldehyde and stained with 2% X-gal substrate (1 mm MgCl 2 , 5 mm K 4 Fe(CN) 6 /K 3 Fe(CN) 6 in PBS) for 4 h at 37°C.
Indirect immunofluorescence
Isolated myofibers were plated on to glass coverslips and infected with G207 as described above. They were then fixed in 1.25% glutaraldehyde in PBS for 15 min, rinsed twice with PBS, followed by 15 min incubation in the blocking solution (PBS with 1% bovine serum albumin (Boehringer Mannheim, Laval, Quebec)). After blocking, myofibers were permeabilized with 0.1% Triton-X100/PBS for 5 min and incubated with a mouse anti-ICP4 antibody at 1:2000 for 1 h. Myofibers were washed with three changes of PBS, then incubated with goat antimouse IgG conjugated to Texas-Red (Jackson Immunochemicals, West Grove, PA, USA) diluted 1:200 in PBS-1% BSA for 30 min. The myofibers were then rinsed with PBS and mounted on glass slides. Immunofluorescence staining was observed using a BioRad MRC 600 confocal epifluorescence microscope. Confocal images were rendered using NIH Image Version 1.60 and colorized with Adobe Photoshop Version 4.0 (Adobe Systems). Standard control experiments were performed, including incubation with the secondary antibody only and with mock infected cells. All fixation and antibody incubations were performed at RT.
In vitro treatment assays
Assays for dextran sulfate stimulation, collagenase type IV, chondroitin ABC lyase, and heparitinase were performed on adult myofibers plated in 24-well dishes. The myofibers were pretreated with varying concentrations of dextran sulfate, collagenase type IV, chondroitin ABC lyase, or heparitinase in DMEM for 30 min before infection. After an overnight adsorption period (approximately 18 h) at 37°C, the inoculum was removed. The myofibers were then fixed for 15 min in 1.25% glutaraldehyde and stained with 2% X-gal substrate for 4 h at 37°C. For all in vitro studies, a minimum of 40 myofibers were tested per treatment group unless otherwise specified.
PEG-induced fusion was performed according to methods described previously. 65 Analysis of glycosaminoglycans Biochemical labeling of glycosaminoglycans was performed by a modification of procedures described previously. 66 Briefly, glycosaminoglycans were radiolabeled by incubating cells for 24 h with 35 S-sulfate (carrier free, approximately 43 Ci/mg, ICN, Costa Mesa, CA, USA) per ml in DMEM/10% FBS/10% horse serum modified to contain 10 m sulfate. The cells were washed three times with cold PBS and solubilized with 1 ml of 0.1 N NaOH at RT for 15 min. Samples were removed for protein determination. Extracts were adjusted to pH 5.5 by the addition of concentrated acetic acid and treated with protease (2 mg/ml) in 0.32 m NaCl-40 mm sodium acetate, pH 5.5, containing shark cartilage chondroitin sulfate (2 mg/ml) as carrier, at 40°C for 12 h. For some experiments, portions of the radioactive material were treated for 12 h at 40°C with 10 mU of chondroitin ABC lyase or 0.5 U of heparitinase. The radioactive products were quantified by chromatography on DEAE-Sephacel (Pharmacia) by binding in 50 mm NaCl followed by elution with 1 m NaCl. For high pressure liquid chromatography (HPLC) analysis, the glycosaminoglycan samples were desalted by precipitation with ethanol. Following centrifugation, the ethanol precipitates were suspended in 20 mm Tris (pH 7.4) and resolved by anion-exchange HPLC, using TSK DEAE-35W column (15 by 75 mm; Beckman Instruments, Mississauga, Ontario). Proteoglycans were eluted from the column by using a linear 50 to 700 mm NaCl gradient formed in 10 mm KH 2 PO 4 (pH 6.0). All buffers contained 0.2% Zwittergent 3-12 (Calbiochem, Hornby, Ontario). The glycosaminoglycans in the peaks were identified by digestion of the sample with the relevant enzymes before chromatography.
Intramuscular administration of the recombinant HSV vector Adult and newborn mice under anesthesia (Ketamine/Rhompun intraperitoneally) were injected percutaneously into the tibialis anterior muscle (TA) to an approximate depth of 2.0 mm using a Hamilton syringe. For in vivo assays involving co-injection of treatment solutions along with the viral inoculum, dextran sulfate, collagenase type IV, or chondroitin ABC lyase was diluted to the appropriate concentration (as identified by in vitro studies) with G207 in an injection volume of 50 l (for adult mice) or 25 l (for newborn mice). Control muscles were injected with G207 only. To evaluate myofiber infection, muscles were removed 3 days after injection for sectioning and histological analysis. For any of the procedures, a minimum of four animals received identical treatment and comprised an experimental group.
Tissue sectioning
The injected and control muscles were frozen in isopentane cooled in liquid nitrogen. Frozen muscles were sectioned, yielding serial cross-sections from one end of the muscle to the other. Cross-sections (10 m) were cut on a cryostat and stained with X-gal and/or hematoxylin and eosin. The sections were retained at regular intervals (approximately every 120 m). For histology, the cryosections were collected on to gelatin-coated glass slides.
Histological analysis
The histological detection of ␤-galactosidase-expressing cells in cryosections was done using X-gal. This compound yields a blue reaction product in cells expressing high levels of ␤-galactosidase. The sections were first fixed by dipping the slides in 4% paraformaldehyde in 100 mm NaP, pH 7.2, for 5 min. The slides were rinsed three times for 5 min in PBS. The sections were then stained with X-gal at a concentration of 1 mg/ml in 5 mm K 3 Fe(CN) 6 , 5 mm K 4 Fe(CN) 6 , 2 mm Mg Cl 2 in PBS for 12 h. The slides were mounted with Permount (Fisher, Nepean, Ontario) and examined microscopically for the presence of ␤-galactosidase-labeled ('blue') myofibers. The total number of lacZ-expressing fibers in a muscle was determined from the section with the maximal number of blue fibers, and that was invariably at the site of implantation.
